• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Swedish Startup says Its Brain Stimulation Headset can Help Treat Depression During COVID-19 Pandemic

Share:

March 31, 2020

Clinical psychologists at medical device firm Flow Neuroscience have offered guidance to support and manage mental health during the COVID-19 pandemic.

The Swedish startup says that its brain stimulation headset is a modern drug-free treatment for depression, which does not require health services, such as the NHS.

Clinical studies published in the New England Journal of Medicine and the British Journal of Psychiatry showed that the type of tDCS brain stimulation used in the Flow headset had a similar impact to antidepressants.

However, the company warns that people suffering from clinical depression should contact their doctor or psychologist if their symptoms worsen.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

It also recommends that to maintain good mental health at this time, people filter news and social media, talk about their feelings by accessing helplines or mental health services if necessary, exercise regularly and eat a healthy diet. The Flow app, free to download on iOS and Android, has advice to improve nutrition and reduce the risk of depression at home.

WHY IT MATTERS

According to the latest statistics from the World Health Organization (WHO), there are 33,2930 confirmed cases of COVID-19 globally, including 171,424 in Europe.

Flow Neuroscience says that its headset can help relieve pressure on health services such as the NHS, which are under strain at this time.

THE LARGER CONTEXT

Flow Neuroscience was founded in 2016 by clinical psychologist Daniel Mansson and neuroscientist Erik Rehn, and consists of prominent researchers in the field of psychiatry, clinical psychology, brain stimulation, neuroscience and machine learning. In July last year, it landed $1.5m in funding in a round led by Khosla Ventures.

Also in 2019, the startup launched a chatbot service to treat depression, which allows users to engage in conversation, track their mood, meditate and download curated video content. Flow Neuroscience has also been working with outpatient clinics in London’s Harley Street district, to offer its brain stimulation headset to patients as an add-on treatment for depression.

During the COVID-19 crisis people have been increasingly turning to digital resources to support good mental health, including online mindfulness courses and apps.

ON THE RECORD

Daniel Mansson, clinical psychologist and co-founder of Flow Neuroscience said: “Global concern about coronavirus means it’s very important to keep the normal routine as much as possible when it comes to sleep, nutrition and exercise, particularly in people with existing mental health problems.

“In the current situation, finding ways to maintain your normal routine is essential to reducing stress and potential depressive thoughts that may appear.”

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Mindstrong Sells Tech Assets to SonderMind, Shuts Down OperationsMindstrong Sells Tech Assets to SonderMind, Shuts Down Operations
  • UnitedHealth to buy health-payments business Equian for $3.2B, report saysUnitedHealth to buy health-payments business Equian for $3.2B, report says
  • Fertility App Premom Shared Users’ Health Data Without Consent, FTC SaysFertility App Premom Shared Users’ Health Data Without Consent, FTC Says
  • Alliancerx Walgreens Prime’s New Function Lets Most Cancers Sufferers Digitally Request Treatment RefillsAlliancerx Walgreens Prime’s New Function Lets Most Cancers Sufferers Digitally Request Treatment Refills
  • Adamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsAdamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
  • Edwards Lifesciences Enters Into Agreement To Acquire CASMEDEdwards Lifesciences Enters Into Agreement To Acquire CASMED
  • ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.
  • Merck Animal Health to Acquire Elanco’s Aqua BusinessMerck Animal Health to Acquire Elanco’s Aqua Business

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications